Jerusalem, Israel

Eilat Shinar

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Macrocure, Ltd.. Active years: 2013-2015.

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eilat Shinar: Innovator in Wound Healing Technologies

Introduction

Eilat Shinar is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of wound healing through his innovative research and development. With a total of 2 patents, Shinar's work focuses on therapeutic compositions derived from blood that promote healing.

Latest Patents

Shinar's latest patents include the development of activated leukocyte compositions and their uses for wound healing. These patents disclose therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using these compositions to repair or promote the prevention and healing of wounds. His research aims to enhance the healing process and improve patient outcomes.

Career Highlights

Eilat Shinar has established himself as a key figure in the medical technology sector. He works at Macrocure, Ltd., where he continues to innovate and develop new solutions for wound care. His expertise in activated leukocyte therapies positions him at the forefront of advancements in this critical area of healthcare.

Collaborations

Shinar collaborates with notable colleagues, including Orit Frenkel and Adi Zuloff-Shani. Together, they work on various projects aimed at enhancing the efficacy of wound healing treatments.

Conclusion

Eilat Shinar's contributions to wound healing technologies through his patents and collaborations highlight his role as an influential inventor in the medical field. His work continues to pave the way for advancements that can significantly improve patient care and recovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…